Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
59 hedge funds and large institutions have $31.3M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 32 closing their positions.
482% more call options, than puts
Call options by funds: $943K | Put options by funds: $162K
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
26% less funds holding
Funds holding: 80 → 59 (-21)
66% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 32
76% less capital invested
Capital invested by funds: $132M → $31.3M (-$101M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$10.4M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$4.3M |
| 3 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.77M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.57M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.9M |
| 2 |
VAM
Visium Asset Management
New York
|
-$10M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.16M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.72M |
| 5 |
Millennium Management
New York
|
-$2.17M |
VIRX Hedge Fund Activity: Q3 2015 in Review
59 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2015, worth a combined $31.3M — down 76% from $132M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of VIRX and 11 opened new positions — a net loss of 21 holders — while 17 trimmed existing stakes and 15 added.
The largest buyer was Palo Alto Investors, adding an estimated $10.4M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $14.9M sold.
- 59 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2015, down from 80 in Q2 2015.
- Funds reported $31.3M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2015, down 76% quarter-over-quarter.
- 11 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2015 and 32 closed out, a net change of -21 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2015 was Palo Alto Investors, an estimated $10.4M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2015 was T. Rowe Price Associates, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2015.